Journal Article

Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza

Hong Zhang

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 62, issue 2, pages 219-223
Published in print August 2008 | ISSN: 0305-7453
Published online January 2008 | e-ISSN: 1460-2091 | DOI: https://dx.doi.org/10.1093/jac/dkn026
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza

Show Summary Details

Preview

Sialidase fusion protein is reported to have great potential to combat seasonal and pandemic influenza, because it may prevent influenza virus infection by removing all sialic acid receptors from host cells. Meanwhile, recent studies have demonstrated that absence of α2-6 sialic acid does not protect a cell from influenza infection, and influenza virus can infect desialylated cells, suggesting that accessible surface sialic acid is dispensable for influenza virus infection. In addition, studies using animal models have shown that neuraminidase promotes adherence and invasion of Streptococcus pneumoniae, because cleavage of sialic acid from host cells exposes cryptic receptors for S. pneumoniae. The purpose of this article is to comment on the benefits and potential risks of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.

Keywords: influenza virus; secondary bacterial pneumonia; animal model

Journal Article.  3644 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.